{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:34:15Z","timestamp":1794249255313,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002163","name":"Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["RA230062"],"award-info":[{"award-number":["RA230062"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["KC240237P1"],"award-info":[{"award-number":["KC240237P1"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["21YOUN33"],"award-info":[{"award-number":["21YOUN33"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210117"],"award-info":[{"award-number":["W81XWH2210117"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.annonc.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:49:42Z","timestamp":1760798982000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-205X","authenticated-orcid":false,"given":"A.W.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8178","authenticated-orcid":false,"given":"W.P.","family":"Skelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-7307","authenticated-orcid":false,"given":"A.J.","family":"Zurita-Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"O.","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"M.T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3798-9970","authenticated-orcid":false,"given":"M.J.M.N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"P.","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8060","authenticated-orcid":false,"given":"N.M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.10.009_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.annonc.2025.10.009_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","author":"Rini","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2025.10.009_bib4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2024.42.4_suppl.362","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial","volume":"42","author":"Bourlon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib5","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10397","key":"10.1016\/j.annonc.2025.10.009_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2025.10.009_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2025.10.009_bib8","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib9","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1470-2045(15)00543-4","article-title":"Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma","volume":"17","author":"Motzer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib10","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.10.009_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.hoc.2023.05.005","article-title":"Managing metastatic renal cell carcinoma after progression on immunotherapy","volume":"37","author":"Barragan-Carrillo","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.annonc.2025.10.009_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urolonc.2024.10.022","article-title":"Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting","volume":"43","author":"Berg","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.hoc.2023.05.006","article-title":"Toxicity management of systemic kidney cancer therapies","volume":"37","author":"Qin","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.annonc.2025.10.009_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pst.2030","article-title":"Bayesian optimal phase II clinical trial design with time-to-event endpoint","volume":"19","author":"Zhou","year":"2020","journal-title":"Pharm Stat"},{"key":"10.1016\/j.annonc.2025.10.009_bib18","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2016.05.049","article-title":"Third-line targeted therapy in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium","volume":"71","author":"Wells","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.10.009_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.009_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.10.009_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2021.12.024","article-title":"Assessing the safety and efficacy of two starting doses of lenvatinib plus everolimus in patients with renal cell carcinoma: a randomized phase 2 trial","volume":"82","author":"Pal","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.10.009_bib23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/fon-2022-0802","article-title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy","volume":"19","author":"Motzer","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/1535-7163.MCT-22-0262","article-title":"Preclinical characterization of XL092, a novel receptor tyrosine kinase inhibitor of MET, VEGFR2, AXL, and MER","volume":"22","author":"Hsu","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2025.10.009_bib26","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1002\/sim.9173","article-title":"The statistical properties of RCTs and a proposal for shrinkage","volume":"40","author":"van Zwet","year":"2021","journal-title":"Stat Med"},{"key":"10.1016\/j.annonc.2025.10.009_bib27","article-title":"Evidenced-based prior for estimating the treatment effect of phase III randomized trials in oncology","volume":"8","author":"Sherry","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2025.10.009_bib28","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/cancers15194674","article-title":"Interpreting randomized controlled trials","volume":"15","author":"Msaouel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2025.10.009_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.9992","article-title":"Evaluating a shrinkage estimator for the treatment effect in clinical trials","volume":"43","author":"van Zwet","year":"2024","journal-title":"Stat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:33:39Z","timestamp":1773866019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425049531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0923753425049531"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}